cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Tcr2 Therapeutics Inc
11 own
8 watching
Current Price
$1.58
$-0.17
(-9.71%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
61.94M
52-Week High
52-Week High
3.88
52-Week Low
52-Week Low
0.821
Average Volume
Average Volume
0.54M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
16.9366
iconMarket Capitalization61.94M
icon52-Week High3.88
icon52-Week Low0.821
iconAverage Volume0.54M
iconDividend Yield--
iconP/E Ratio16.9366
What does the Tcr2 Therapeutics Inc do?
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline comprise TC-220, a TRuC-T cell that targets MUC16 positive solid tumors; TC-310, a dual TRuC-T cells targeting both CD19 and CD22; and TC-410, a dual TRuC-T cell targeting both mesothelin and MUC16. The company has a cooperative research and development agreement with the National Cancer Institute to collaborate on the use of TCR2 proprietary T cell receptor Fusion Construct T cells as a cancer therapeutic agent against mesothelin in Phase I/II clinical trial of TC-210. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Tcr2 Therapeutics Inc make?
News & Events about Tcr2 Therapeutics Inc.
PR Newswire
1month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR PR Newswire NEW YORK, April 27, 2023 NEW YORK, April 27, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the...
Business Wire
1month ago
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of TCR Therapeutics Inc. (NasdaqGS: TCRR) to Adaptimmune Therapeutics plc (NasdaqGS: ADAP). Under the terms of the proposed transaction...
PR Newswire
1month ago
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR PR Newswire NEW YORK, April 11, 2023 NEW YORK, April 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the...
PR Newswire
1month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR PR Newswire NEW YORK, April 6, 2023 NEW YORK, April 6, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the...
Frequently Asked Questions
Frequently Asked Questions
What is Tcr2 Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Tcr2 Therapeutics Inc shares?
plus_minus_icon
How can I buy Tcr2 Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Tcr2 Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Tcr2 Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Tcr2 Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Tcr2 Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Tcr2 Therapeutics Inc?
plus_minus_icon
What percentage is Tcr2 Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Tcr2 Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.58
$-0.17
(-9.71%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$1.00
$-0.01 (-1.48 %)
IMMUNIC INC
IMMUNIC INC
$1.71
$0.06 (3.64 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.12
$0.02 (1.82 %)
Passage Bio Inc
Passage Bio Inc
$1.02
$0.02 (1.57 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$1.00
$-0.01 (-1.48 %)
IMMUNIC INC
IMMUNIC INC
$1.71
$0.06 (3.64 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.12
$0.02 (1.82 %)
Passage Bio Inc
Passage Bio Inc
$1.02
$0.02 (1.57 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00